PUT - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 13:43:57 2024-05-24 EDT | ||
| 7.91 EUR | -6.94% |
|
| Current month | -42.56% | ||
| 1 month | -39.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 7.91 | -6.94% |
| 24-05-23 | 8.5 | -1.51% |
| 24-05-22 | 8.63 | -9.44% |
| 24-05-21 | 9.53 | +9.29% |
| 24-05-20 | 8.72 | -3.75% |
Real-time Boerse Frankfurt Warrants
Last update May 24, 2024 at 01:43 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM8ZVW |
| ISIN | DE000VM8ZVW8 |
| Date issued | 2024-01-23 |
| Strike | 539.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.02 € |
|---|---|
| Lowest since issue | 7.91 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
